The value of 99mTc-MIBI whole body scintigraphy in active and in remission multiple myeloma

Hellenic Journal of Nuclear Medicine

Volumn 8, Issue 3, 2005, Pages 165-168

  Fallahi, Babak ^a   Saghari, Mohsen ^a   Esfahani, Armaghan Fard ^a   Eftekhari, Mohammad ^a   Iravani, Masood ^a   Beiki, Davood ^a   Kakhki, Vahid R Dabbagh ^a   Sadeghi, Ramin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

99mTc MIBI; Active disease; Follow up; Multiple myeloma diagnosis

Indexed keywords

ALKALINE PHOSPHATASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOISOTOPE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOELECTROPHORESIS; IRAN; MALE; MULTIPLE MYELOMA; NON INVASIVE MEASUREMENT; OBSERVER VARIATION; PREDICTION; PROTEIN BLOOD LEVEL; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; WHOLE BODY SCINTISCANNING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; STATISTICS; TUMOR REGRESSION; WHOLE BODY IMAGING;

FEMALE; HUMANS; IRAN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM REGRESSION, SPONTANEOUS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; WHOLE BODY IMAGING;

EID: 30344461593     PISSN: 17905427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Yun M, Kim C, Sam J, et al. Bone marrow scintigraphy. In: Sandler MP, Coleman RE, Patton JA, et al. Diagnostic nuclear medicine. Philadelphia, Williams & Wilkins; 2003: 576-577.
2. Van der Wall H. The evaluation of malignancy: Metastatic bone disease. In: Murray IPC, Ell PJ, Vander wall H, Starauss HW. Nuclear medicine in clinical diagnosis and treatment. Hong Kong, Churchill, Livingstone; 1998: 1179.
3. Gahrton C, Durie BGM. Multiple myeloma. 1st edn New York, USA: Arnold publ. 1996.
4. Prodalof DA. Malignant bone disease. In: Henkin RE, Bolos MA, Karesh SM, et al. Nuclear medicine. St. Louis, Mosby; 1996: 1217.
5. Scutellari PN, Spanedda R, Feggi LM, Cervi PM. The value and limitations of total body scan in the diagnosis of MM: a comparison with conventional radiography. Hematologica 1985; 70: 136-142.
6. Salomon SE, Cassady JR. Plasma cell neoplasm. In: De Vita VT Jr, Hellman SH, Rosenburg SA, et al. Cancer-principles and practice of oncology. Philadelphia New York: Lippincott-Raven; 1997: 2344-2387.
7. Pace L, Catalano L, Pinto A, et al. Different patterns of technetium-99m sestamibi uptake in multiple myeloma. Eur J Nucl Med 1998; 25: 714-720.
8. Wakasugi S, Teshima H, Nakamura H, et al. Tc-99m MIBI localization in bone marrow: A marker of bone marrow malignancy. Clin Nucl Med 1998; 23: 664-671.
9. Tirovola EB, Biassoni L, Britton KE, et al. The use of Tc-99m MIBI scanning in multiple myeloma. Br J Cancer 1996; 74: 1815-1820.
10. Fonti R, Del Vecchie S, Zannet A, et al. Bone marrow uptake of Tc-99m MIBI in patients with multiple myeloma. Eur J Nucl Med 2001; 28: 214-220.
11. Alexandrakis MG, Kyriakou DS, Porsam F, et al. Value of Tc-99m sestamibi scintigraphy in the detection of bone lesions in multiple myeloma: comparison with Tc-99m methylene diphosphonate. Ann Hematol 2001; 80: 349-353.
12. Pace L, Catalano L, Delvecchio S, et al. Predictive value of Tc-99m MIBI in patients with multiple myeloma and potential role in the follow-up. Eur J Nucl Med 2001; 28: 304-312.
13. Svaldi M, Tappa C, Gebertu, et al. Tc-99m-MIBI scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem-cell transplantation. Ann Hematol 2001; 80: 393-397.
14. Wasser K, Moehler T, Nosas-Garcia S, et al. Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma. Fortshr Röntgenstr 2005; 177:1116-1122.
15. Lecouvet FE, Vande Berg BC, Maldague BE, et al. Vertebral compression fractures in multiple myeloma. Part I. Distribution and appearance at MR imaging. Radiology 1997; 204: 195-199.
16. An HS, Andreshak TG, Nguyen C, et al. Can we distinguish between benign versus malignant compression fractures of the spine by magnetic resonance imaging? Spine 1995; 20: 1776-1782.
17. Ballinger JR, Hua HA, Berry BW, et al. Tc-99m sestamibi as an agent for imaging P-glycoprotein mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995; 16: 253-257.
18. Moretti JL, Gaglar M, Duran-Cordobes M, Morere JF. Can nuclear medicine predict response to chemotherapy? Eur J Nucl Med 1995; 22: 97-100.